Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 31-year-old user experienced hair regrowth and no side effects after switching from finasteride to dutasteride and using minoxidil foam daily. They reported improved hair retention and shared their treatment routine, including a prescription for dutasteride and the use of minoxidil, while humorously discussing side effects and personal experiences.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The conversation is about using finasteride and testosterone replacement therapy (TRT) for hair loss and their role in gender-affirming care. It debates whether these treatments are considered hormone replacement therapy (HRT) and their implications for both cisgender and transgender individuals.

The conversation discusses differences in hair shaft diameter and density between thinning and denser areas on the scalp. Treatments mentioned include Minoxidil, finasteride, and dutasteride.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.